Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager

Bispecific antibodies have attracted more attention in recent years for the treatment of tumors, in which most of them target CD3, which mediates the killing of tumor cells by T cells. However, T-cell engager may cause serious side effects, including neurotoxicity and cytokine release syndrome. More...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Xinghui, Cheng, Ying, Zheng, Xiaodong, Fang, Yuhang, Zhang, Yu, Sun, Rui, Tian, Zhigang, Sun, Haoyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126364/
https://www.ncbi.nlm.nih.gov/pubmed/37114050
http://dx.doi.org/10.3389/fimmu.2023.1113303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126364/
https://www.ncbi.nlm.nih.gov/pubmed/37114050
http://dx.doi.org/10.3389/fimmu.2023.1113303

Ejemplares similares